Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. The model was based on 100 patients from the healthcare payer perspective in the UK, France, Italy, Spain, and Germany (5-year time horizon). Co...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical economics 2022-12, Vol.25 (1), p.1068-1075
Hauptverfasser:	Mancuso, Maria Elisa, Castaman, Giancarlo, Pochopien, Michal, Aballéa, Samuel, Drzewiecka, Aleksandra, Hakimi, Zalmai, Nazir, Jameel, Fatoye, Francis
Format:	Artikel
Sprache:	eng
Schlagworte:	cost savings Cost-minimization modeling emicizumab hemophilia A recombinant factor VIII Fc wastage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!